title: Rationale for the use of trastuzumab in patients with cerebral metastases who previously receive trastuzumab-based therapy for metastatic breast cancer.
authors.forename: Kadri
authors.initials: K
authors.lastname: Altundag
authors.forename: Ozden
authors.initials: O
authors.lastname: Altundag
authors.forename: Mustafa Ata
authors.initials: MA
authors.lastname: Atik
authors.forename: Paolo
authors.initials: P
authors.lastname: Morandi
authors.forename: Mehmet
authors.initials: M
authors.lastname: Gunduz
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001812:Blood-Brain Barrier / Q000528:radiation effects; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D005260:Female; D006801:Humans; D011878:Radiotherapy; D000068878:Trastuzumab; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab